Themis Medicare Ltd. (THEMISMED): Themis Medicare Share Price Rises 8.88% as Micro Cap Stock Clears Threshold
- August 17, 2026
- Posted by: Harsh Piplani
- Category: News
Themis Medicare Share Price moved sharply higher to Rs 114 on 17 August 2026, up 8.88% from the previous close of Rs 104.7, putting the pharmaceuticals stock among the notable market movers in early trade. With a market capitalisation of Rs 964.29 crore, Themis Medicare Ltd.< For investors tracking Themis Medicare Share Price Today, the data confirms a strong single-day price rise, even though the supplied data does not establish a company-specific catalyst behind the move.
That distinction matters. In Stock Market Today coverage, many stocks trend because of results, orders, management commentary or broader sector moves. Here, the verified data clearly establishes the price event and its size, but not a specific trigger. Even so, Themis Medicare Stock News is relevant because the stock opened at Rs 114 and traded at Rs 114 as the day’s high and low at the time of capture, showing an immediate repricing versus the prior close. That makes Themis Medicare Share Price Rise a fact-based event worth analysing through price action, profitability, valuation and peer comparison.
For readers looking up Why Themis Medicare Is Rising Today, the safest answer is this: the stock is trending because it rose 8.88% in one session and crossed the required bar for a micro cap top gainer screen. The important financial metrics also provide context. The company trades at a P/E ratio of 24.12 and a P/B ratio of 2.49, while ROE stands at 17.82 and ROCE at 18.44. Investors tracking Themis Medicare Share Price on Univest should now monitor whether the move sustains, how it compares with industry benchmarks, and whether valuation and profitability continue to support investor attention.
Themis Medicare Ltd. (THEMISMED) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 114 |
| Previous Close | Rs 104.7 |
| Today's Change | +Rs 9.3 (+8.88%) |
| Day Open | Rs 114 |
| Day High | Rs 114 |
| Day Low | Rs 114 |
| Current Volume (BSE) | 1 |
| BSE Traded Volume | 1 |
| NSE Traded Volume | 2 |
| Combined NSE + BSE Volume | 3 |
| Turnover | Rs 0 crore |
| Market Capitalisation | Rs 964.29 crore |
| Market Cap Category | Micro Cap |
Themis Medicare Ltd. (THEMISMED) traded at Rs 114. versus the previous close of Rs 104.7, a rise of 8.88%. The stock opened at Rs 114, reached Rs 114, touched Rs 114. Reported volume was 1.
Themis Medicare Ltd. (THEMISMED) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 964.29 crore |
| P/E Ratio | 24.12x |
| P/B Ratio | 2.49x |
| ROE | 17.82% |
| ROCE | 18.44% |
| EPS | Rs 4.34 |
| Dividend Yield | 0.48% |
Themis Medicare Ltd. was valued at a P/E ratio of 24.12x, a P/B ratio of 2.49x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.
Profitability and capital efficiency were represented by ROE of 17.82% and ROCE of 18.44%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.
Per-share and shareholder-return metrics included EPS of Rs 4.34, dividend yield of 0.48%. Dividend yield is a current or historical ratio and does not guarantee future distributions.
Themis Medicare Fundamental Analysis shows a micro cap pharmaceutical company with profitable return ratios and mid-range valuation multiples relative to its industry data. While today’s move was driven by price action rather than a verified disclosed catalyst in the dataset, the stock’s fundamentals offer enough context to explain why investors may still be tracking it closely.
Themis Medicare Ltd. has a market capitalisation of Rs 964.29 crore, which is much larger than the industry median market cap of Rs 137.8 crore and also above the industry average of Rs 481.52 crore across 139 companies in the same industry benchmark. Market capitalisation alone does not signal quality, but it does place the company above a large part of the listed Pharmaceuticals & Drugs universe used in this comparison. The available dataset does not provide enterprise value, debt or cash-flow numbers, so the cleanest valuation anchors here are P/E and P/B.
Themis Medicare Share Price is associated with a P/E ratio of 24.12 and a P/B ratio of 2.49. EPS stands at 4.34, which represents the earnings attributable to each share based on the supplied data. Dividend yield is 0.48, which indicates the historical or current payout relative to the market price rather than any assured future distribution. The dataset does not provide book value per share, so valuation discussion remains centred on the reported P/B multiple rather than per-share net worth.
Profitability metrics are more constructive. ROE is 17.82 and ROCE is 18.44, both suggesting that the company is generating returns materially above the industry medians of 9.91 for ROE and 12.79 for ROCE. Compared with the industry averages of 7.3 for ROE and 14.83 for ROCE, the company also sits ahead on both measures. That matters because Themis Medicare Share Price Today is not only about momentum; it also reflects a business whose reported returns on equity and capital are stronger than a broad same-industry sample.
At the same time, the P/B ratio of 2.49 is above the industry median of 1.77 and slightly above the industry average of 2.33, so investors looking at Themis Medicare Stock Analysis should balance above-benchmark profitability against somewhat richer book-value-based valuation. Overall, the supplied fundamentals add real context to investor interest without turning the analysis into a recommendation. The next step is to place Themis Medicare Share Price within its sector and peer landscape.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 24.12x |
| Benchmark Median P/E | 26.47x |
| Benchmark Average P/E | 40.28x |
| Benchmark P/E Range | 2.98x to 361.02x |
| Company P/B Ratio | 2.49x |
| Benchmark Median P/B | 1.77x |
| Company ROE | 17.82% |
| Benchmark Median ROE | 9.91% |
| Company ROCE | 18.44% |
| Benchmark Median ROCE | 12.79% |
| Company Market Capitalisation | Rs 964.29 crore |
| Benchmark Median Market Cap | Rs 137.8 crore |
Themis Medicare Ltd. (THEMISMED) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Themis Medicare Ltd. (THEMISMED) has a P/E ratio of 24.12x, which is below the benchmark median of 26.47x, a difference of -8.88%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Themis Medicare Ltd. (THEMISMED) has a ROE of 17.82%, which is above the benchmark median of 9.91%, a difference of +79.82%. Themis Medicare Ltd. (THEMISMED) has a ROCE of 18.44%, which is above the benchmark median of 12.79%, a difference of +44.18%.
Track today’s top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.
Themis Medicare Share Price is best understood within the Healthcare sector and Pharmaceuticals & Drugs industry, where the supplied benchmark covers 139 same-industry companies. Relative to that universe, the company appears larger than the typical peer by market value, trades at a lower-than-median P/E, but shows stronger profitability on both ROE and ROCE.
The sector snapshot identifies Themis Medicare Ltd. under Healthcare and specifically within Pharmaceuticals & Drugs. The benchmark scope is explicitly described as the same industry, with 139 companies in the comparison set. That breadth matters because it gives a meaningful frame for valuation and operating quality rather than relying on a very narrow sample.
On valuation, Themis Medicare Share Price trades at a company P/E of 24.12. That is below the industry median P/E of 26.47 and well below the industry average P/E of 40.28, based on 105 companies with P/E data. The benchmark range also shows just how wide pharmaceutical valuations can be in this segment, from a minimum of 2.98 to a maximum of 361.02. On this basis alone, Themis Medicare does not screen as an outlier on earnings multiple relative to the industry set.
The P/B ratio tells a slightly different story. The company’s P/B of 2.49 is above the median of 1.77 and modestly above the average of 2.33 across 138 companies, within a range of -21.33 to 27.19. So book-value valuation is somewhat richer than the centre of the industry distribution even if earnings valuation is more moderate.
Profitability is where the company compares more favourably. ROE at 17.82 is comfortably above the median of 9.91 and the average of 7.3. ROCE at 18.44 is also above the median of 12.79 and the average of 14.83. Market capitalisation of Rs 964.29 crore is far above the industry median of Rs 137.8 crore and above the average of Rs 481.52 crore, though still well below the industry maximum of Rs 2,985.15 crore. For investors reading Themis Medicare Share Price News Today on Univest, the sector data suggests a stock with stronger-than-benchmark returns and a moderate earnings multiple inside a diverse pharma peer set.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Dishman Carbogen Amcis Ltd. | DCAL | 2,985.15 | 184.72 | 0.45 | -2.89 | -0.26 |
| Beta Drugs Ltd. | BETA | 2,827.67 | 68.16 | 6.74 | 18.65 | 22.17 |
| Hikal Ltd. | HIKAL | 2,686.72 | 0 | 2.26 | 15.22 | 16.15 |
| Ind-Swift Laboratories Ltd. | INDSWFTLAB | 2,645.37 | 46.15 | 1.77 | -0.78 | 8.31 |
| Fredun Pharmaceuticals Ltd. | FREDUN | 2,559.68 | 58.41 | 8.73 | 11.42 | 13.15 |
Themis Medicare Ltd. (THEMISMED) has a P/E ratio of 24.12x compared with the displayed peer median of 58.41x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 17.82% compares with a peer median of 11.42% across the companies shown in the table. ROCE stood at 18.44% versus the displayed peer median of 13.15%, providing a capital-efficiency comparison. Themis Medicare Ltd. (THEMISMED) has a market capitalisation of Rs 964.29 crore. Among the 5 peers shown, 5 have a larger market capitalisation.
Themis Medicare Share Price also becomes more informative when placed against named listed peers from the same Healthcare and Pharmaceuticals & Drugs space. The supplied peer set includes companies such as Dishman Carbogen Amcis, Beta Drugs, Hikal, Ind-Swift Laboratories, Fredun Pharmaceuticals, Solara Active Pharma Sciences, Sai Parenteral’s, Panacea Biotec, Venus Remedies and NGL Fine-Chem.
On market capitalisation, Themis Medicare Ltd. at Rs 964.29 crore is smaller than every named peer in the supplied list, where the lowest peer market cap shown is NGL Fine-Chem at Rs 2,139.2 crore and the highest is Dishman Carbogen Amcis at Rs 2,985.15 crore. That means Themis Medicare Share Price belongs to a materially smaller listed company than the direct comparison names, even though it is above its broader industry median size.
Valuation-wise, the company’s P/E of 24.12 is far below Dishman Carbogen Amcis at 184.72, Beta Drugs at 68.16, Ind-Swift Laboratories at 46.15, Fredun Pharmaceuticals at 58.41, Sai Parenteral’s at 171 and NGL Fine-Chem at 37.4. It is, however, above Venus Remedies at 20.56 among peers where P/E is available. That places Themis Medicare in the lower half of this peer valuation sample on earnings multiple.
Its P/B ratio of 2.49 sits above Dishman Carbogen Amcis at 0.45, Hikal at 2.26, Ind-Swift Laboratories at 1.77 and Solara at 1.93, but below Beta Drugs at 6.74, Fredun Pharmaceuticals at 8.73, Sai Parenteral’s at 3.13, Panacea Biotec at 2.9, Venus Remedies at 3.48 and NGL Fine-Chem at 6.15. So on book-value valuation, the stock is neither particularly cheap nor especially stretched within this peer basket.
Profitability is mixed but credible. ROE of 17.82 is stronger than Hikal at 15.22, Fredun at 11.42, Sai Parenteral’s at 13.9, Panacea Biotec at 0, Venus Remedies at 9.85 and Dishman Carbogen Amcis at -2.89, while remaining slightly below Beta Drugs at 18.65 and well below NGL Fine-Chem at 27.9. ROCE of 18.44 is above Hikal at 16.15, Fredun at 13.15, Sai Parenteral’s at 12.97, Panacea Biotec at 5.36, Venus Remedies at 7.89, Ind-Swift at 8.31, Solara at 15.34 and Dishman Carbogen Amcis at -0.26, but below Beta Drugs at 22.17 and NGL Fine-Chem at 33.91. For readers following Themis Medicare Share Price Update, that peer picture suggests relatively balanced valuation and respectable return ratios despite the smaller market size.
Why Investors Are Watching Themis Medicare
Themis Medicare Share Price is being watched because today’s move was not just a routine uptick. The stock rose 8. Even without a verified company-specific trigger in the supplied dataset, that combination of price action and cross-sectional ranking is enough to make the stock relevant in daily Market News and Stock Updates.
- Verified price action: The stock moved from Rs 104.7 to Rs 114, a gain of Rs 9.3 or 8.88%.
- Category context: It is classified as a Micro Cap stock and cleared the exact threshold required for that segment.
- Fundamental profile: P/E is 24.12, P/B is 2.49, ROE is 17.82, ROCE is 18.44, EPS is 4.34 and dividend yield is 0.48.
- Sector positioning: P/E is below industry median and average, while ROE and ROCE are above both benchmark levels.
- Peer positioning: The company is smaller than the named peers but compares reasonably on profitability and earnings multiple.
What investors should monitor next is whether Themis Medicare Share Price holds above the previous close after this sharp repricing, how consistently market participation develops beyond the thin turnover snapshot, and whether the stock continues to compare well on profitability against the Pharmaceuticals & Drugs benchmark on Univest. That is a monitoring framework, not a recommendation.
About Themis Medicare
Themis Medicare Ltd. is part of the Healthcare sector and operates within the Pharmaceuticals & Drugs industry. The supplied data set does not include a long-form company description, product list or segment-wise revenue mix, so the most reliable way to place the business is through its industry classification and market metrics.
As a Pharmaceuticals & Drugs company, Themis Medicare sits inside a listed industry universe where 139 companies are used for same-industry comparison in the benchmark snapshot. Within that set, its market capitalisation of Rs 964.29 crore is well above the median of Rs 137.8 crore and above the average of Rs 481.52 crore. That means the company is not among the smallest names in the industry sample, even though it is still categorised as a Micro Cap for the purposes of today’s event screen.
Themis Medicare Share Price is also supported by profitability metrics that compare favourably with the broader industry sample. ROE of 17.82 and ROCE of 18.44 both sit above the benchmark medians and averages, indicating stronger returns than many same-industry companies. At the same time, a P/E of 24.12 and P/B of 2.49 place the stock in a valuation range that is neither at the low extreme nor the high extreme of the benchmark distribution.
For readers tracking Themis Medicare Latest News, the most important company-level takeaway from the supplied data is simple: this is a listed pharmaceutical stock with above-benchmark return ratios, a mid-range earnings multiple and a share price that has moved sharply enough today to become a verified top gainer event.
Track Themis Medicare Share Price on Univest
Use Themis Medicare Ltd. (THEMISMED) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.
Themis Medicare Share Price can be tracked on Univest for live market movement, price action context and deeper stock analysis. Users following Themis Medicare Share Price Today can monitor current price, daily percentage change, market capitalisation, valuation ratios such as P/E and P/B, profitability indicators including ROE and ROCE, and broader sector comparison within Healthcare and Pharmaceuticals & Drugs.
Univest also helps investors follow share price trends alongside 52-week levels, market insights, peer comparison, and company fundamentals in one place. For anyone searching Themis Medicare Share Price Live, Themis Medicare Share News or Themis Medicare Stock News, the goal is not to push a recommendation but to make the available data easier to track, compare and understand in the context of the Indian stock market.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why is Themis Medicare Share Price rising today?
Ans. Themis Medicare Share Price rose because the stock gained 8.88% in today’s session, moving from Rs 104.7 to Rs 114.
What is Themis Medicare Share Price Today?
Ans. Themis Medicare Share Price Today was Rs 114 at the captured time in the dataset. That was Rs 9.3 above the previous close of Rs 104.7, translating into a one-day gain of 8.88%.
How much did Themis Medicare stock gain today?
Ans. Themis Medicare stock gained Rs 9.3 in absolute terms and 8.88% in percentage terms. That move was enough to place it in a verified price rise event screen for a Micro Cap stock.
What is the market capitalisation of Themis Medicare Ltd.?
Ans. Themis Medicare Ltd. had a market capitalisation of Rs 964.29 crore in the supplied data. Within the same industry benchmark, that is above the median market cap of Rs 137.8 crore and the average of Rs 481.52 crore.
Is Themis Medicare expensive compared with its industry P/E?
Ans. Based on the supplied benchmark, Themis Medicare’s P/E of 24.12 is below the industry median of 26.47 and well below the industry average of 40.28. On earnings multiple alone, it does not look above benchmark.
How does Themis Medicare compare on profitability?
Ans. Themis Medicare reports ROE of 17.82 and ROCE of 18.44. Both are above the same-industry medians of 9.91 and 12.79, and also ahead of the benchmark averages of 7.3 and 14.83.
What are the key valuation ratios for Themis Medicare?
Ans. The key reported valuation ratios are P/E of 24.12 and P/B of 2.49. The company also has EPS of 4.34 and a dividend yield of 0.48, adding useful context to current market pricing.
How does Themis Medicare compare with named pharma peers?
Ans. Themis Medicare is smaller by market cap than all named peers in the supplied list, but its P/E of 24.12 is below many peer readings. Its ROE and ROCE compare favourably against several pharmaceutical companies.
What does today’s volume data show for Themis Medicare?
Ans. The supplied snapshot shows very light activity in absolute terms, with current volume at 1, BSE volume at 1, NSE volume at 2 and total volume at 3. Reported turnover for the snapshot was Rs 0 crore.
What should investors monitor after this Themis Medicare Share Price rise?
Ans. Investors can monitor whether Themis Medicare Share Price sustains above the previous close of Rs 104.7, whether broader trading participation improves, and how valuation and profitability continue to compare with the Pharmaceuticals & Drugs benchmark.
